Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Flex-a-New on Osteoarthritis of the Knee

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2006 by Rabin Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Rabin Medical Center
ClinicalTrials.gov Identifier:
NCT00294801
First received: February 21, 2006
Last updated: NA
Last verified: February 2006
History: No changes posted

February 21, 2006
February 21, 2006
January 2006
Not Provided
KOOS
Same as current
No Changes Posted
VAS KSS
Same as current
Not Provided
Not Provided
 
Effect of Flex-a-New on Osteoarthritis of the Knee
Not Provided

comparative trial of placebo versus flex-a-new (a food supplement) containing glucosamine an chondroitin sulfate for the symptom modification is knee osteoarthritis

comparative trial of placebo versus flex-a-new (a food supplement) containing glucosamine an chondroitin sulfate for the symptom modification is knee osteoarthritis

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Osteoarthritis
Drug: flex-a-new (food supplement)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
80
December 2007
Not Provided

Inclusion Criteria:

knee osteoarthritis grade 1 to 3 -

Exclusion Criteria:

ischemic heart disease with CHF -

Both
18 Years to 85 Years
No
Israel
 
NCT00294801
flex-a-new
Not Provided
Not Provided
Rabin Medical Center
Not Provided
Principal Investigator: dror robinson Rabin Medical Center
Rabin Medical Center
February 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP